THE VALUE OF THE REGISTER WITH INFLAMMATORY BOWEL DISEASE TO ASSESS THE EFFECTIVENESS OF DIAGNOSTIC AND TREATMENT ACTIVITIES
Abstract
Inflammatory bowel diseases (IBD) are chronic recurrent immune-mediated inflammation of the gastrointestinal tract. Now it is not unified system of monitoring patients with IBD in Russia, but there is information from different regions about the prevalence of disease. There are the registers in few big cities. From 2003 the registers of IBD have been done in Novosibirsk. The register data can give us the possibility to estimate the various real-time data of the disease, to analyze the effect of the treatment , to evaluate risk factors for the disease in real clinical practice. Among the patients with ulcerative colitis decreased the number of patients with recurrent and continuous increase in the number of patients with distal forms, which is probably due to the more skillful conduct of patients. In general, it decreased the number of patients with Crohn's disease with continuously relapsing course option, reflecting, perhaps, improved treatment. Decline in the proportion of persons with the localization process, only in the colon, which is associated with greater availability of diagnostic methods for destruction of the small intestine. The registry was created in April 2012 and includes patients registered up to October 2015.
About the Authors
M. F. Osipenko
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
E. Yu. Valuyskih
Institution of the Russian Academy of Medical Sciences Research Institute for internal medicine of Siberian Branch RAMS
Russian Federation
Russian Federation
I. O. Svetlova
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Yu. A. Kulygina
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
M. I. Skalinskaya
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
E. A. Bikbulatova
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
Ya. A. Krasner
Novosibirsk State Medical University, Russian Ministry of Health
Russian Federation
Russian Federation
References
1. Satsangi J, Silverberg M. S., Vermeire S.,. Colombel J. F. The Montreal classification of inflammatory bowel disease: controversies, consensus and implications. Gut. 2006, № 55, pp 749-753.
2. Long M, Hutfless S., Kappelman M. D., Khalili H., et all. Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. Inflamm Bowel Dis, 2014, № 20 (2), pp. 398-415.
3. Ye Y, Pang Z, Chen W, Ju S, Zhou C. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med. 2015, vol.8 (12), pp. 22529-22542.
4. Simian D., Fluxá D., Flores L., Lubascher J, et al. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol. 2016 June 14, vol. 22 (22), pp. 5267-5275.
5. Воробьев Г. И., Халиф И. Л. Неспецифические воспалительные заболевания кишечника. - М.: Миклош, 2008, 400 с.
6. Халиф И. Л. Воспалительные заболевания кишечника: современные возможности и нерешенные проблемы в лекарственной терапии. Consilium Medicum. 2015, № 1, С. 33-34.
7. Ng W. K., Wong S. H., Ng S. C. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016, vol.14 (2), pp. 111-119.
8. Адлер Г. Болезнь Крона и язвенный колит. - М.: ГЕОТАР-МЕД., 2001, 527 с.
9. Gearry R. B. IBD and Environment: Are There Differences between East and West. Dig Dis. 2016, vol. 34 (1-2), pp 84-89.
10. Ягудина Р. И., Литвиненко М. М., Сороковиков И. В. Регистры пациентов: структура, функции, возможности использования. Фармакоэкономика. Том 4. № 4, 2011, С. 3-7.
11. Victoria CR, Sassak LY, Nunes HR. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq Gastroenterol, 2009, vol., pp. 46: 20-25 [PMID: 19466305 DOI: 10.1590/S0004-28032009000100009].
12. Yepes I, Carmona R, Díaz F, Marín-Jiménez I. Prevalence and demographic characteristics of inflammatory bowel disease in Cartagena, Colombia. Rev Col Gastroenterol. 2010, vol. 25, pp.106-109.
13. Ng SC, Zeng Z, Niewiadomski O, Tang W, et all. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. Gastroenterology. 2016, vol. 150, pp. 86-95.e3; quiz e13-4 [PMID: 26385074 DOI: 10.1053/ j.gastro.2015.09.005]
14. Satsangi J, Silverberg M. S., Vermeire S., Colomb J. F., el all. The Montreal classification of inflammatory bowel disease: controversies, consensus and implications. Gut. 2006, vol. 55, pp. 749-753.
15. Валуйских Е. Ю., Светлова И. О., Курилович С.А. и др. Клинико-генетические аспекты воспалительных заболеваний кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008, 18 (6), С. 68-75.
16. Валуйских Е. Ю., Светлова И. О., Курилович С. А. и др. Полиморфизм генов регуляторов воспаления при неспецифическом язвенном колите и болезни Крона. Бюллетень СО РАМН. 2009, 2 (136), C.81-89.
17. Zaharie R, Tantau A, Zaharie F, Tantau M, et al. Diagnostic Delay in Romanian Patients with Inflammatory Bowel Disease: Risk Factors and Impact on the Disease Course and Need for Surgery. J Crohns Colitis. 2016 Mar, 10 (3), pp. 306-314.
18. Ливзан М. А., Долгих Т. И., Лялюкова Е. А. Фекальный кальпротектин в комплексной диагностике заболеваний кишечника. Экспериментальная и клиническая гастроэнтрология. 2013, № 1, С 83-86.
19. Parente JM, Coy CS, Campelo V, et al. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. World J Gastroenterol 2015; vol. 21, pp.1197-1206.
20. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel iseases. Gastroenterology, 2011, vol.140, pp.1785-1794.
21. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006, vol.12, pp.4819-4831 [PMID: 16937463 DOI: 10.3748/wjg.v12.i30.4819].
22. Rocchi A, Benchimol E. I., Bernstein C. N., et al. Inflammatory bowel disease: A Canadian burden of illness review. Can J Gastroenterol. 2012 Nov, 26 (11), pp. 811-817.
23. Ливзан М. А., Макейкина М. А. Неспецифический язвенный колит: генетика иммунного ответа. Клин. перспективы гастроэнтерологии, гепатологии. 2012, № 1, С. 28-33.
24. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population- cohort study 1977-2011. Am J Gastroenterol 2015, vol.110: 564-571 [PMID:25803400 DOI: 10.1038/ajg.2015.50].
Review
For citations:
Osipenko M.F., Valuyskih E.Yu., Svetlova I.O., Kulygina Yu.A., Skalinskaya M.I., Bikbulatova E.A., Krasner Ya.A. THE VALUE OF THE REGISTER WITH INFLAMMATORY BOWEL DISEASE TO ASSESS THE EFFECTIVENESS OF DIAGNOSTIC AND TREATMENT ACTIVITIES. Experimental and Clinical Gastroenterology. 2016;(9):42-47. (In Russ.)
Views:
314
Email this article 